Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam lands $38.6 million federal government contract
Viral hemorrhagic fevers are considered by federal agencies to be high priority agents that pose a risk to national security because they can be easily disseminated from person
Viral hemorrhagic fevers are considered by federal agencies to be high priority agents that pose a risk to national security because they can be easily disseminated from person
The approved trial is a randomized, placebo controlled, double-blind Phase II trial investigating 1mg/day of Tasq (ABR-215050) versus placebo in 200 patients. The trial will be performed in
A total of 265 patients have been admitted to the trial. Completion of the trial data analysis is expected in the last quarter of 2007. The effect of
“Working with Merck in this discovery collaboration, we identified and successfully validated essential tumor maintenance genes suitable for development of small molecule agents in multiple AVEO cancer models,”
MELAS syndrome (mitochondrial encephalopathy lactic acidosis and stroke-like episodes) is a progressive and fatal disorder caused by a mutation in the DNA of the mitochondria that mainly affects
Peptech will acquire 100% of the issued shares in EvoGenix for A$0.15 cash and 0.5055 Peptech shares for each EvoGenix share held. The merged entity, to be renamed,
SPI-1620 is being developed as an adjunct to chemotherapy. The highly selective endothelin-B agonist has demonstrated in experimental animal models a transient and selective increase in blood flow
Rhein Minapharm, Cairo-based Minapharm’s biotechnology subsidiary, will exclusively market Elafin in Egypt, Middle Eastern and African countries. Proteo will receive an upfront payment, milestone-payments and royalties on net
Preliminary analysis of the study results indicates DOV 21,947 was safe and well-tolerated at the doses examined and produced a significant decline in plasma triglyceride levels. The company
US regulators reviewed the drugs after two clinical trials suggested that they increased the risk of heart attacks and cardiac death. Nexium and Prilosec are proton pump inhibitors